PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego. "We are very pleased to participate in this year's Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world," ...

During the conference, Prashant Kohli, Chief Executive Officer of Acasti, will host meetings with pharmaceutical executives to explore partnership and strategic opportunities for the Company's asset portfolio. To connect during the conference, please request a meeting via the BIO International meeting portal or contact mmoyer@lifesciadvisors.com. PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its ...

WALL, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced today that on May 22, 2024, it received a letter (the "Notification Letter") from The Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required per ...

BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 2024, in San Diego, California. Event: BIO International Convention Date: June 3-6, 2024 Presentati ...

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADP ...

Core Insights - BIO-key International, Inc. is set to file its audited 2023 results with the SEC on Form 10-K next week and will also report its Q1 2024 results by the end of next week [1] - The company has engaged Bush & Associates CPA as its independent registered public accounting firm as of April 23, 2024 [2] - BIO-key specializes in biometric-centric, multi-factor identity and access management (IAM) solutions, securing access for over 40 million users [3] Company Developments - The upcoming filing of audited results indicates a commitment to transparency and regulatory compliance [1] - The engagement of a new accounting firm may reflect a strategic move to enhance financial oversight and reporting accuracy [2] - BIO-key's IAM solutions offer passwordless, phoneless, and token-less authentication options, catering to diverse user needs [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-07928 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject ...

Bio-Rad Laboratories, Inc. (BIO) posted first-quarter 2024 adjusted earnings per share (EPS) of $2.29, beating the Zacks Consensus Estimate by 12.3%. However, the bottom line declined 31.4% from the prior-year quarter’s levels.The quarter’s adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments.The company’s GA ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Andy Last - Executive Vice President and COO Roop Lakkaraju - CFO Conference Call Participants Patrick Donnelly - Citi Selena Lu - UBS Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Operator Good afternoon everyone, and welcome to today's Bio-Rad First Quarter 2024 Earnings Results Conference ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $3.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.25%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.93 per share when it actually produced earnings of $3.10, delivering a surprise of 5.8 ...